UB
CLDX icon

UMB Bank’s Celldex Therapeutics CLDX Stock Holding History

UMB Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$68 – 2092
2024
Q3 		$68 Hold
2
– – ﹤0.01% 2132
2024
Q2 		$74 Hold
2
– – ﹤0.01% 2127
2024
Q1 		$84 Hold
2
– – ﹤0.01% 2137
2023
Q4 		$79 Hold
2
– – ﹤0.01% 1596
2023
Q3 		$55 Hold
2
– – ﹤0.01% 1682
2023
Q2 		$68 Hold
2
– – ﹤0.01% 1671
2023
Q1 		$72 Hold
2
– – ﹤0.01% 1683
2022
Q4 		$0 Hold
2
– – ﹤0.01% 1730
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1784
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1911
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1986
2021
Q4 		$0 Buy
+2
New +$87 ﹤0.01% 1975

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UMB Bank's CLDX Position: Q4 2024 in Review

UMB Bank sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 2 shares — an estimated $68 sold.

UMB Bank first reported a position in CLDX in Q4 2021 and held it in 12 quarters. The position peaked at $84 in Q1 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • UMB Bank reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • UMB Bank sold 2 Celldex Therapeutics shares in Q4 2024, an estimated $68.
  • UMB Bank first reported a position in Celldex Therapeutics in Q4 2021 and held it in 12 quarters.
  • UMB Bank's Celldex Therapeutics position peaked at $84 in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on UMB Bank's 13F filing for Q4 2024, filed 16 Jan 2025.